Table 4.
Comparison of the stimulation variables and clinical outcomes between the spontaneously falling E2 group and the drug dosage reduction group.
| Variables | Spontaneously reduction (n = 63) | Dose-adjusted reduction (n = 57) | P value |
|---|---|---|---|
| Starting dosage of Gn used (IU) | 156.55 ± 49.23 | 174.55 ± 56.51 | 0.068 |
| Duration of Gn used (d) | 16.38 ± 4.38 | 13.37 ± 2.66 | <0.001 |
| Total dosage of Gn used (IU) | 3147.22 ± 1448.74 | 2250.32 ± 888.53 | <0.001 |
| Endometrial thickness on hCG day (mm) | 11.07 ± 2.41 | 11.11 ± 1.90 | 0.920 |
| LH level on the hCG day (IU/L) | 0.59 ± 0.58 | 0.56 ± 0.36 | 0.744 |
| E 2 level on the hCG day (pg/ml) | 1517.31 ± 936.48 | 2330.37 ± 1296.09 | <0.001 |
| P level on the hCG day (ng/mL) | 0.54 ± 0.30 | 0.60 ± 0.31 | 0.284 |
| Number of oocytes retrieved (n) | 11.19 ± 5.50 | 14.77 ± 5.46 | 0.001 |
| Rate of high-quality embryos (%) | 0.77 ± 0.26 | 0.81 ± 0.20 | 0.299 |
| Blastocysts available rate (%) | 0.40 ± 0.30 | 0.51 ± 0.28 | 0.053 |
| Clinical pregnancy rate (%) | 61.90% (39/63) | 54.39% (31/57) | 0.404 |
| Early abortion rate (%) | 17.95% (7/39) | 19.35% (6/31) | 0.881 |
| Ongoing pregnancy rate (%) | 50.79% (32/63) | 43.86% (25/57) | 0.448 |
| Live birth rate (%) | 47.62% (30/63) | 38.60% (22/57) | 0.319 |
hCG, human chorionic gonadotropin; Gn, gonadotropin.